Search Results - "CZIBERE, A" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

by Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.
Published in Annals of oncology (01.11.2020)

Get full text

Journal Article

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

by Schroeder, T, Czibere, A, Platzbecker, U, Bug, G, Uharek, L, Luft, T, Giagounidis, A, Zohren, F, Bruns, I, Wolschke, C, Rieger, K, Fenk, R, Germing, U, Haas, R, Kröger, N, Kobbe, G
Published in Leukemia (01.06.2013)

Get full text

Journal Article

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

by Schroeder, T, Fröbel, J, Cadeddu, R-P, Czibere, A, Dienst, A, Platzbecker, U, Bug, G, Uharek, L, Fenk, R, Germing, U, Kröger, N, Haas, R, Kobbe, G
Published in Leukemia (01.09.2013)

Get full text

Journal Article

Core-binding factor leukemia hijacks the T-cell–prone PU.1 antisense promoter

Core-binding factor leukemia hijacks the T-cell–prone PU.1 antisense promoter

by van der Kouwe, E., Heller, G., Czibere, A., Pulikkan, J.A., Agreiter, C., Castilla, L.H., Delwel, R., Di Ruscio, A., Ebralidze, A.K., Forte, M., Grebien, F., Heyes, E., Kazianka, L., Klinger, J., Kornauth, C., Le, T., Lind, K., Barbosa, I.A.M., Pemovska, T., Pichler, A., Schmolke, A.-S., Schweicker, C.M., Sill, H., Sperr, W.R., Spittler, A., Surapally, S., Trinh, B.Q., Valent, P., Vanura, K., Welner, R.S., Zuber, J., Tenen, D.G., Staber, P.B.
Published in Blood (14.10.2021)

Get full text

Journal Article

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

by Yu, Y., Elmeliegy, M., Litton, J.K., Tudor, I.C., Czibere, A., Zheng, J., Wang, D.D.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on≥1 novel hormonal therapy (NHT)

TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on≥1 novel hormonal therapy (NHT)

by de Bono, J.S., Higano, C., Saad, F., Miller, K., Casey, M., Czibere, A., Healy, C., Fizazi, K.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials

by Elmeliegy, M., Yu, Y., Litton, J.K., Turner, N.C., Czibere, A., Wilson, G.G., Tudor, I.C., Zheng, J., Wang, D.D.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

by Czibere, A, Bruns, I, Kröger, N, Platzbecker, U, Lind, J, Zohren, F, Fenk, R, Germing, U, Schröder, T, Gräf, T, Haas, R, Kobbe, G
Published in Bone marrow transplantation (Basingstoke) (01.05.2010)

Get full text

Journal Article

The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence

by Bruns, I, Czibere, A, Fischer, J C, Roels, F, Cadeddu, R-P, Buest, S, Bruennert, D, Huenerlituerkoglu, A N, Stoecklein, N H, Singh, R, Zerbini, L F, Jäger, M, Kobbe, G, Gattermann, N, Kronenwett, R, Brors, B, Haas, R
Published in Leukemia (01.05.2009)

Get full text

Journal Article

Sorafenib (Nexavar® ) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

Sorafenib (Nexavar® ) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

by Safaian, N.N, Czibere, A, Bruns, I, Fenk, R, Reinecke, P, Dienst, A, Haas, R, Kobbe, G
Published in Leukemia research (01.02.2009)

Get full text

Journal Article

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY

by Mohty, M, Tomasson, M, Arnulf, B, Bahlis, N, Prince, M, Niesvizky, R, Rodrgue-Otero, P, Martine-Lopez, J, Koehne, G, Jethava, Y, Gabayan, A, Stevens, D, Nooka, A, Raje, N, Iida, S, Leip, E, Conte, U, Czibere, A, Viqueira, A, Blunk, V, Lesokhin, A
Published in Hematology, Transfusion and Cell Therapy (01.10.2023)

Get full text

Journal Article

Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT

Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT

by Kobbe, G, Bruns, I, Fenk, R, Czibere, A, Haas, R
Published in Bone marrow transplantation (Basingstoke) (01.05.2009)

Get full text

Journal Article

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3

by Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez‐Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.‐S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.
Published in HemaSphere (23.06.2022)

Get full text

Journal Article

$Bendamustine in patients with relapsed or refractory multiple myeloma$

Bendamustine in patients with relapsed or refractory multiple myeloma

by Michael, M, Bruns, I, Bölke, E, Zohren, F, Czibere, A, Safaian, N N, Neumann, F, Haas, R, Kobbe, G, Fenk, Roland
Published in European journal of medical research (29.01.2010)

Get full text

Journal Article

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy

by Bruennert, D, Czibere, A, Bruns, I, Kronenwett, R, Gattermann, N, Haas, R, Neumann, F
Published in Leukemia (01.05.2009)

Get full text

Journal Article

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma

by Kobbe, G., Bruns, I., Schroeder, T., Czibere, A., Warnecke, J., Hieronimus, N., Safaian, N., Kondakci, M., Saure, C., Germing, U., Haas, R., Fenk, R.
Published in Annals of oncology (01.09.2010)

Get full text

Journal Article

Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases

Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases

by Zohren, F, Schroeder, T, Czibere, A, Fenk, R, Bruns, I, Kondakci, M, Saure, C, Haas, R, Kobbe, G
Published in Bone marrow transplantation (Basingstoke) (01.05.2011)

Get full text

Journal Article

Fludarabine, amsacrine, high-dose cytarabine and 12Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia

Fludarabine, amsacrine, high-dose cytarabine and 12Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia

by Zohren, F, Czibere, A, Bruns, I, Fenk, R, Schroeder, T, Graef, T, Haas, R, Kobbe, G
Published in Bone marrow transplantation (Basingstoke) (13.12.2009)

Get full text

Journal Article

O-004 New minimal-invasive diagnostic procedures for patients with myelodysplastic syndromes by profiling the deep serum proteome

O-004 New minimal-invasive diagnostic procedures for patients with myelodysplastic syndromes by profiling the deep serum proteome

by Fröbel, J, Hartwig, S, Germing, U, Kündgen, A, Zilkens, C, Schroeder, T, Haas, R, Czibere, A, Lehr, S
Published in Leukemia research (01.05.2013)

Get full text

Journal Article

Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia

Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia

by Zohren, F, Czibere, A, Bruns, I, Fenk, R, Schroeder, T, Gräf, T, Haas, R, Kobbe, G
Published in Bone marrow transplantation (Basingstoke) (01.12.2009)

Get full text

Journal Article